📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-08 18:54
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
26 announcements match the current filters (relevance ≥ 5).
Evervie Health Pre-pays ₹13.46 Cr NCD Interest Due Across Dec 2026 and Mar 2027
Evervie Health Limited (formerly PVP Ventures Limited) has paid ₹13.46 Cr in advance on 08 October 2026 towards scheduled interest on its Non-Convertible Debentures. The payment covers two upcoming quarters: contractual due dates of 31 December 2026 and 31 March 2027. The interest relates to Series A (₹95 Cr issue size) and Series B (₹55 Cr issue size) debentures, totaling ₹150 Cr in aggregate principal. This prepayment indicates immediate liquidity headroom to service its high-coupon debt obligations.
Confidence: HIGH
What changedEvervie Health cleared two upcoming quarters of NCD interest payments ahead of schedule on 08 October 2026.
Why it mattersDemonstrates near-term liquidity to service ₹150 Cr in high-cost debt, mitigating default risk for the next two quarters.
Total advance interest paid: ₹13.46 CrSeries A issue size: ₹95,00,00,000Series B issue size: ₹55,00,00,000Advance interest vs TTM revenue: ~11.4%
📅 Short termPositive sentiment for credit health, removing near-term debt servicing uncertainty through Q4 FY27.
📈 Long termLimited; structural debt reduction and cash flow visibility from Project Rainbow and healthcare ventures remain essential for sustainable deleveraging.
⚠ Risk flags
- High finance cost load with total debt at ₹207 Cr against net worth of ₹214 Cr
Key Highlights
Prepaid total interest of ₹13.46 Cr in advance on 08 October 2026
Covers two future quarterly cycles due on 31 December 2026 and 31 March 2027
₹8.53 Cr paid on Series A debentures (issue size ₹95 Cr)
₹4.94 Cr paid on Series B debentures (issue size ₹55 Cr)
👀 What to Watch
Track operating cash flows from real estate inventory liquidation and healthcare operations in upcoming quarterly results to verify ongoing debt servicing sustainability.
PVP Ventures CEO & COO Resign w.e.f. September 24, 2026 Prior to Joining
PVP Ventures announced the resignation/cessation of both Dr. Ellen Jane Feehan (Executive Director & CEO) and Dr. Neeraja Nagarajan (Executive Director & COO), effective September 24, 2026. Dr. Feehan cited unavoidable personal and health reasons, terminating her Executive Employment Agreement (signed July 6, 2026) prior to her scheduled joining date of October 1, 2026. Dr. Nagarajan resigned following the non-alignment of Dr. Feehan, citing leadership differentials and personal commitments in the United States. This leaves the top executive management vacant just as the company attempts to pivot into healthcare operations.
Confidence: HIGH
What changedBoth the incoming CEO and COO have stepped down and terminated their executive engagements effective September 24, 2026.
Why it mattersThe sudden exit of both the top operating executives disrupts PVP's strategic pivot into healthcare services and leaves leadership continuity uncertain.
Effective cessation date: 24-09-2026Original joining date (CEO): 1st October 2026EEA execution date: 1st July 2026
📅 Short termNegative sentiment around governance and leadership stability following the abrupt double departure at the executive level.
📈 Long termCreates execution uncertainty for the company's strategic pivot toward healthcare (Evervie Health / Humain Healthtech) until new leadership is established.
⚠ Risk flags
- Key management vacancy at CEO and COO levels simultaneously
- Execution delays in the healthcare strategy rollout
Key Highlights
Resignation of both Executive Director & CEO (Dr. Ellen Jane Feehan) and Executive Director & COO (Dr. Neeraja Nagarajan) effective September 24, 2026.
Dr. Feehan terminated her Executive Employment Agreement signed on July 6, 2026 ab initio ahead of the October 1, 2026 start date.
Dr. Nagarajan resigned due to the departure of Dr. Feehan, leadership structure differences, and US domicile requirements.
Cessations impact PVP Ventures' planned leadership team for its healthcare pivot (Evervie Health).
👀 What to Watch
Watch for board announcements regarding interim appointments or new hires for the CEO and COO positions to lead the company's healthcare ventures.
PVP Ventures Executive Director & COO Dr. Neeraja Nagarajan Resigns Effective Sept 24, 2026
PVP Ventures Limited has announced the resignation of Dr. Neeraja Nagarajan from her position as Executive Director & Chief Operating Officer (COO), effective September 24, 2026. The resignation was tendered citing personal reasons. PVP Ventures operates in residential real estate and healthcare services with a market cap of ₹395 Cr and TTM revenue of ₹118 Cr.
Confidence: HIGH
What changedDr. Neeraja Nagarajan has stepped down from her operational leadership role as Executive Director and COO effective September 24, 2026.
Why it mattersA sudden departure of the COO may create short-term operational execution uncertainty in real estate projects and the scaling healthcare business.
Date of cessation: 24-09-2026Market cap: ₹395 CrTTM Revenue: ₹118 Cr
📅 Short termWatch for the announcement of interim leadership or a new COO to handle day-to-day operations.
📈 Long termLimited, provided the core promoter-led management team remains intact and project execution timelines are maintained.
⚠ Risk flags
- Key managerial turnover at the executive level
- Operational disruption during ongoing healthcare pivot and real estate launches
Key Highlights
Dr. Neeraja Nagarajan resigned as Executive Director & COO
Cessation date effective September 24, 2026
Reason stated is personal reasons
Company indicated disclosures under Clause 7(C) will follow in due course
👀 What to Watch
Track announcements regarding the appointment of a successor COO and monitor whether this impacts the operational rollout of ongoing projects like Project Mercury.
PVP Ventures: Executive Director & COO Dr. Neeraja Nagarajan Resigns Effective Sep 24, 2026
PVP Ventures Limited has informed stock exchanges of the immediate resignation of Dr. Neeraja Nagarajan from her position as Executive Director & Chief Operating Officer (COO), effective September 24, 2026. The departure is attributed to personal reasons, with detailed regulatory disclosures under Clause 7(C) to follow. While the exchange subject line initially referenced another executive, the official formal filing confirms Dr. Nagarajan's exit. Given PVP's market cap of Rs 395 Cr and ongoing execution across residential and healthcare initiatives, senior management continuity remains critical.
Confidence: HIGH
What changedDr. Neeraja Nagarajan stepped down from her dual roles as Executive Director and Chief Operating Officer effective September 24, 2026.
Why it mattersThe COO position oversees day-to-day operations during a key phase of residential project liquidation and healthcare integration.
Date of cessation: 24-09-2026Company Market Cap: Rs 395 CrTTM Revenue: Rs 118 Cr
📅 Short termLimited share price impact expected as operational leadership transitions, though market will look for details on succession.
📈 Long termLimited structural impact unless accompanied by broader operational delays in project delivery or key strategic milestones.
⚠ Risk flags
- Key person risk / operational leadership vacancy during project execution phases
Key Highlights
Dr. Neeraja Nagarajan resigned as Executive Director & COO effective September 24, 2026
Reason cited for cessation is personal reasons
Filing made under Regulation 30(6) read with SEBI Master Circular dated January 30, 2026
Further detailed disclosures under Clause 7(C) of Para A of Schedule III to follow
👀 What to Watch
Track announcements regarding the appointment of a new COO to oversee operational projects like Project Mercury and Project Rainbow.
PVP Ventures: Executive Director & COO Dr. Neeraja Nagarajan Resigns Effective Sep 24, 2026
PVP Ventures Limited has informed stock exchanges of the immediate resignation of Dr. Neeraja Nagarajan from her position as Executive Director & Chief Operating Officer (COO), effective September 24, 2026. The departure is attributed to personal reasons, with detailed regulatory disclosures under Clause 7(C) to follow. While the exchange subject line initially referenced another executive, the official formal filing confirms Dr. Nagarajan's exit. Given PVP's market cap of Rs 395 Cr and ongoing execution across residential and healthcare initiatives, senior management continuity remains critical.
Confidence: HIGH
What changedDr. Neeraja Nagarajan stepped down from her dual roles as Executive Director and Chief Operating Officer effective September 24, 2026.
Why it mattersThe COO position oversees day-to-day operations during a key phase of residential project liquidation and healthcare integration.
Date of cessation: 24-09-2026Company Market Cap: Rs 395 CrTTM Revenue: Rs 118 Cr
📅 Short termLimited share price impact expected as operational leadership transitions, though market will look for details on succession.
📈 Long termLimited structural impact unless accompanied by broader operational delays in project delivery or key strategic milestones.
⚠ Risk flags
- Key person risk / operational leadership vacancy during project execution phases
Key Highlights
Dr. Neeraja Nagarajan resigned as Executive Director & COO effective September 24, 2026
Reason cited for cessation is personal reasons
Filing made under Regulation 30(6) read with SEBI Master Circular dated January 30, 2026
Further detailed disclosures under Clause 7(C) of Para A of Schedule III to follow
👀 What to Watch
Track announcements regarding the appointment of a new COO to oversee operational projects like Project Mercury and Project Rainbow.
PVP Ventures: Executive Director & COO Dr. Neeraja Nagarajan Resigns Effective Sep 24, 2026
PVP Ventures Limited has informed stock exchanges of the immediate resignation of Dr. Neeraja Nagarajan from her position as Executive Director & Chief Operating Officer (COO), effective September 24, 2026. The departure is attributed to personal reasons, with detailed regulatory disclosures under Clause 7(C) to follow. While the exchange subject line initially referenced another executive, the official formal filing confirms Dr. Nagarajan's exit. Given PVP's market cap of Rs 395 Cr and ongoing execution across residential and healthcare initiatives, senior management continuity remains critical.
Confidence: HIGH
What changedDr. Neeraja Nagarajan stepped down from her dual roles as Executive Director and Chief Operating Officer effective September 24, 2026.
Why it mattersThe COO position oversees day-to-day operations during a key phase of residential project liquidation and healthcare integration.
Date of cessation: 24-09-2026Company Market Cap: Rs 395 CrTTM Revenue: Rs 118 Cr
📅 Short termLimited share price impact expected as operational leadership transitions, though market will look for details on succession.
📈 Long termLimited structural impact unless accompanied by broader operational delays in project delivery or key strategic milestones.
⚠ Risk flags
- Key person risk / operational leadership vacancy during project execution phases
Key Highlights
Dr. Neeraja Nagarajan resigned as Executive Director & COO effective September 24, 2026
Reason cited for cessation is personal reasons
Filing made under Regulation 30(6) read with SEBI Master Circular dated January 30, 2026
Further detailed disclosures under Clause 7(C) of Para A of Schedule III to follow
👀 What to Watch
Track announcements regarding the appointment of a new COO to oversee operational projects like Project Mercury and Project Rainbow.
Acuité assigns 'ACUITE BBB-/Stable' rating to PVP Ventures' ₹150 Cr NCDs
Acuité Ratings & Research has assigned an investment-grade rating of 'ACUITE BBB- | Stable' to PVP Ventures Limited's Non-Convertible Debentures (NCDs) aggregating to ₹150.00 Cr. The rated facilities include two long-term tranches of ₹95.00 Cr (ISIN INE362A07054) and ₹55.00 Cr (ISIN INE362A07047). The ₹150.00 Cr rated instruments account for roughly 72.5% of the company's total debt of ₹207 Cr. This rating establishes formal credit benchmarks for the company's long-term borrowing facilities.
Confidence: HIGH
What changedAcuité Ratings assigned a formal credit rating of 'ACUITE BBB-/Stable' to ₹150 Cr of PVP Ventures' long-term Non-Convertible Debentures across two ISINs.
Why it mattersAchieving an investment-grade rating on ₹150 Cr of debt (~72.5% of total debt) validates PVP's creditworthiness and provides institutional visibility for its long-term borrowing structure.
Total NCDs Rated: ₹150.00 CrNCD Tranche 1 (INE362A07054): ₹95.00 CrNCD Tranche 2 (INE362A07047): ₹55.00 CrRated Debt vs Total Debt: ~72.5%Credit Rating Assigned: ACUITE BBB- | Stable
📅 Short termNeutral to mildly positive for market sentiment as the formal BBB- investment grade credit rating confirms credit standing on listed debentures.
📈 Long termFacilitates stable borrowing relationships and sets expectations for credit performance as project execution and monetization unfold over FY26-FY30.
⚠ Risk flags
- High debt burden with ₹207 Cr total debt against ₹214 Cr net worth (D/E of 0.97)
- Significant project execution and cash flow dependency for servicing debt obligations
Key Highlights
Acuité assigned 'ACUITE BBB-
Stable' rating to ₹150.00 Cr of long-term NCDs on September 02, 2026
NCD Tranche 1 (ISIN INE362A07054) covers ₹95.00 Cr in long-term debentures
NCD Tranche 2 (ISIN INE362A07047) covers ₹55.00 Cr in long-term debentures
Rated debt of ₹150.00 Cr represents ~72.5% of PVP's total debt (₹207 Cr) and ~70% of net worth (₹214 Cr)
👀 What to Watch
Monitor upcoming quarterly interest servicing costs and operational cash flows from residential projects to ensure cash coverage ratios remain adequate for debt obligations.
PVP Ventures: Corrigendum on ₹5 Cr CMD Remuneration & 5-Year Re-Appointment
PVP Ventures has issued a corrigendum to Item No. 10 of its 35th AGM notice scheduled for September 7, 2026. The revised special resolution seeks shareholder approval for the re-appointment of Mr. Prasad V. Potluri as Chairman & Managing Director for a 5-year term ending in 2031. It also seeks approval for managerial remuneration of ₹5.00 crore for FY 2026-27 even in the absence or inadequacy of profits. Additionally, the resolution approves payment of fees to the CMD at 2% p.a. on collateral securities and 1% p.a. on personal guarantees provided for company borrowings.
Confidence: HIGH
What changedPVP Ventures amended the AGM notice to explicitly include the 5-year re-appointment of CMD Prasad V. Potluri alongside approval of ₹5 Cr remuneration and guarantee fee payouts.
Why it mattersThe ₹5 Cr remuneration (representing ~4.2% of TTM revenue of ₹118 Cr) plus 1–2% recurring guarantee fees add to annual corporate overheads for a company carrying ₹207 Cr debt and recent net losses.
Proposed CMD Remuneration: Rs.5,00,00,000Remuneration vs TTM Revenue: ~4.2%Collateral Fee Rate: 2% per annumPersonal Guarantee Fee Rate: 1% per annumCMD Re-appointment Term: 5 yearsAGM Date: 07th September 2026
📅 Short termFocus remains on the AGM outcome on September 7, 2026, and whether public/institutional shareholders support the remuneration and guarantee fee structure.
📈 Long termContinued payouts of ₹5 Cr remuneration and credit enhancement fees will influence cash flow generation as the company executes Project Mercury and services its debt obligations.
⚠ Risk flags
- High managerial remuneration relative to net profitability
- Related-party transaction fees on collateral and guarantees
- Inadequate historical profit coverage
Key Highlights
Re-appointment of Mr. Prasad V. Potluri as CMD for a 5-year term from 35th AGM till AGM 2031
Approval sought for ₹5.00 crore managerial remuneration for FY 2026-27 under Schedule V
Proposed fee of 2% p.a. on value of collateral securities provided by CMD for company credit facilities
Proposed fee of 1% p.a. on value of personal guarantees extended by CMD for borrowings
AGM scheduled to be held on 07th September 2026
👀 What to Watch
Track shareholder voting results from the 35th AGM on September 7, 2026, specifically regarding the approval of the special resolution for managerial remuneration and guarantee fees.
PVP Ventures to Rename as Evervie Health; Proposes ₹73 Cr Related Party Transactions
PVP Ventures has issued a notice for its 35th AGM on September 07, 2026, proposing a strategic name change to 'Evervie Health Limited' to reflect its pivot into healthcare services. The company is seeking shareholder approval for material related party transactions (RPTs) totaling ₹73 Cr for FY27, which is significant given its TTM revenue of ₹90 Cr. Additionally, a new 'PVP ESOP Scheme 2026' is proposed, which includes the issuance of new shares that may exceed 1% of the current share capital. The company also plans to appoint M/s. CNGSN & Associates LLP as statutory auditors for a five-year term.
Confidence: HIGH
What changedThe company is formalizing its business pivot from construction to healthcare through a corporate rebranding and a new employee stock option framework.
Why it mattersThe name change signals a definitive long-term strategy shift; however, the high volume of related party transactions (81% of TTM revenue) requires close monitoring for corporate governance.
Total Proposed RPTs: ₹73 CrRPTs vs TTM Revenue: 81.1%ESOP Allotment Limit: >1% of share capitalAuditor Term: 5 yearsAGM Date: September 07, 2026
📅 Short termThe market may react positively to the clarity provided by the rebranding, though the focus will remain on the upcoming AGM resolutions.
📈 Long termThe structural shift to 'Evervie Health' is critical as the company attempts to move away from its loss-making construction legacy (₹-10 Cr TTM PAT) toward healthcare services.
⚠ Risk flags
- High value of Related Party Transactions (₹73 Cr)
- Equity dilution from new ESOP issuance
- Geographic concentration in Chennai
Key Highlights
Proposed name change to 'Evervie Health Limited' to align with the strategic shift into healthcare diagnostics and imaging.
Approval sought for ₹73 Cr in material related party transactions across 8 entities for FY27.
Introduction of PVP ESOP Scheme 2026 involving the issuance of new shares to employees.
Appointment of M/s. CNGSN & Associates LLP as Statutory Auditors for a 5-year term until 2031.
AGM scheduled for September 07, 2026, with a voting cut-off date of August 31, 2026.
👀 What to Watch
Investors should monitor the AGM voting results, specifically the approval of the ₹73 Cr RPTs and the potential equity dilution from the new ESOP scheme.
PVP Ventures Reports ₹15.11 Cr Net Profit in Q1 FY27; CEO Designation Corrected
PVP Ventures reported a significant turnaround in Q1 FY27 with a net profit of ₹15.11 Cr, compared to ₹0.78 Cr in the year-ago period. This performance was heavily bolstered by 'Other Income' of ₹25.43 Cr, which offset an exceptional loss of ₹10.85 Cr. The company also clarified the appointment of Dr. Ellen Jane Feehan as CEO, correcting a previous misclassification. However, a substantial related-party loan of ₹218.43 Cr remains outstanding, with repayment now extended to March 2028.
Confidence: HIGH
What changedThe company returned to significant profitability in Q1 FY27 and corrected its top leadership structure by designating Dr. Ellen Jane Feehan as CEO.
Why it mattersThe shift to profitability is a positive signal, but the high reliance on non-operational income and the large related-party loan (exceeding the company's net worth) remain critical financial focal points.
Q1 Net Profit: 1,511.16 LakhsOther Income: 2,542.93 LakhsRelated Party Loan: 21,843.49 LakhsLoan vs Net Worth: ~102%Finance Cost: 890.18 Lakhs
📅 Short termThe stock may react positively to the headline profit growth and the formalization of the CEO's role.
📈 Long termLong-term value depends on the successful execution of the Chennai real estate projects and the actual cash recovery of the large related-party loan.
⚠ Risk flags
- High related-party loan exposure (21,843.49 Lakhs)
- Reliance on non-operational income for profitability
- High finance costs relative to operational revenue
Key Highlights
Net profit surged to 1,511.16 Lakhs in Q1 FY27 from 78.19 Lakhs in Q1 FY26.
Other Income contributed 2,542.93 Lakhs, significantly exceeding operational revenue of 1,349.27 Lakhs.
Outstanding interest-free secured loan to related party NCCPL stands at 21,843.49 Lakhs.
Exceptional loss of 1,085.00 Lakhs was recognized during the quarter.
Security cover for listed NCDs is maintained at 3.86x on a market value basis.
👀 What to Watch
Investors should monitor the sustainability of operational revenue as 'Other Income' currently drives the bottom line. Watch for the launch of Project Mercury in Q3FY26 and the recovery of the 21,843.49 Lakhs related-party loan by the 2028 deadline.
PVP Ventures Reports ₹15.11 Cr Net Profit in Q1 FY27; Appoints Dr. Ellen Jane Feehan as CEO
PVP Ventures reported a standalone net profit of ₹15.11 Cr for Q1 FY27, a significant turnaround from ₹0.78 Cr in the year-ago period. Total income rose to ₹38.92 Cr, though this was heavily supported by ₹25.43 Cr in 'Other Income'. The company also formalized the appointment of Dr. Ellen Jane Feehan as CEO and Executive Director, correcting a previous administrative error. Management continues to monitor a ₹218.43 Cr loan to related party NCCPL, which has been extended to March 2028.
Confidence: HIGH
What changedThe company reported a sharp increase in quarterly profitability and corrected its leadership structure by formally designating Dr. Ellen Jane Feehan as CEO.
Why it mattersThe high profitability helps improve the company's net worth and debt-servicing capability for its 18% high-cost NCDs. Leadership stability is crucial as the company pivots from media to healthcare and Chennai-based real estate.
Q1 Net Profit: ₹15.11 CrQ1 Revenue from Operations: ₹13.49 CrOther Income: ₹25.43 CrRelated Party Loan (NCCPL): ₹218.43 CrLoan vs Net Worth: ~102%
📅 Short termThe stock may react positively to the headline profit growth and the formalization of the CEO role over the coming weeks.
📈 Long termThe long-term outlook depends on the monetization of the 70-acre Chennai land parcel and the successful integration of the Humain Healthtech acquisition.
⚠ Risk flags
- High reliance on non-operational 'Other Income' for profitability
- Significant related-party loan exposure (₹218.43 Cr)
- High finance costs (₹8.90 Cr in Q1) relative to operational revenue
Key Highlights
Net profit increased to ₹15.11 Cr in Q1 FY27 from ₹0.78 Cr in Q1 FY26
Revenue from operations grew 46.8% YoY to ₹13.49 Cr
Other Income of ₹25.43 Cr accounted for 65.3% of the total income for the quarter
Security cover ratio based on market value for listed NCDs stands at 3.86x
Outstanding loan to related party NCCPL remains at ₹218.43 Cr with repayment extended to 2028
👀 What to Watch
Investors should monitor the source of 'Other Income' to determine if it is a recurring gain or a one-off asset sale. Additionally, watch for the launch of 'Project Mercury' in Q3 FY26 as a key driver for operational revenue growth.
PVP Ventures increases stake in 7 Med India to 41.23% as part of Rs 127 Cr healthcare pivot
PVP Ventures has completed the second tranche of its acquisition of 7 Med India Private Limited, increasing its stake to 41.23% through the purchase of 4,263 additional shares. The total planned outlay for a 50.62% majority stake is approximately Rs 127 crore, which is highly material as it represents ~141% of PVP's TTM revenue of Rs 90 crore. 7 Med India is a top-five organized player in India's renal care (dialysis) sector, facilitating PVP's strategic pivot into healthcare. The company remains committed to acquiring the remaining stake to reach 50.62% ownership.
Confidence: HIGH
What changedPVP Ventures has increased its ownership in 7 Med India from an associate level to 41.23%, moving closer to becoming the majority shareholder.
Why it mattersThis is a significant capital allocation that shifts the company's profile from construction to healthcare, potentially providing more stable cash flows to service its high-cost 18% NCD debt.
Total Deal Outlay: Rs 127 crCurrent Stake: 41.23%Target Stake: 50.62%Deal Value vs TTM Revenue: ~141%Deal Value vs Net Worth: ~59.3%
📅 Short termThe market is likely to view the progress of this large-scale acquisition positively as it clarifies the company's diversification strategy.
📈 Long termIf successfully integrated, the renal care business could fundamentally re-rate PVP from a construction firm to a healthcare-led conglomerate, though high debt servicing remains a long-term hurdle.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High deal value relative to current revenue
- Execution risk in a new business sector (Healthcare)
- High debt levels (Rs 207 Cr) with 18% interest obligations
Key Highlights
Acquired 4,263 additional equity shares, raising total stake to 41.23%
Total transaction outlay estimated at circa Rs 127 crore for a 50.62% majority stake
Target entity 7 Med India is a top-five organized player in India's renal care sector
Deal value represents approximately 59% of PVP Ventures' current net worth of Rs 214 crore
Acquisition is being funded via cash consideration as part of a strategic healthcare expansion
👀 What to Watch
Monitor the timeline for the final tranche to reach 50.62% and the subsequent impact on consolidated margins, as the company is currently loss-making at the PAT level.
PVP Ventures Defers Rs 150 Cr NCD Principal Repayment to June 2027
PVP Ventures has amended its Debenture Trust Deed to defer the principal repayment of Rs 150 Cr in Non-Convertible Debentures (NCDs) by one year, moving the start date from June 2026 to June 2027. The debt is held by LICHFL funds and carries a high interest rate of 18%. This move provides temporary liquidity relief for the loss-making company (TTM PAT of Rs -10 Cr) as it prepares for the launch of Project Mercury in Q3FY26. However, the high cost of debt and the deferment highlight underlying cash flow pressures.
Confidence: HIGH
What changedThe company successfully negotiated a 12-month extension for the start of principal repayments on its Rs 150 Cr NCDs, originally due in June 2026.
Why it mattersThis deferment prevents an immediate liquidity crunch but increases the long-term interest burden at a high 18% rate, making the company's turnaround contingent on timely real estate project completions.
Deferred Principal Amount: Rs 150 CrDeferred Amount vs TTM Revenue: 166.67%NCD Interest Rate: 18%New Repayment Start Date: June 2027Total Debt: Rs 207 Cr
📅 Short termNeutral. The deferment removes immediate default risk and provides a 12-month breathing room, which may be viewed as a tactical positive by the market.
📈 Long termHigh risk. The company remains structurally challenged by high-cost debt and a loss-making bottom line; long-term stability depends entirely on the Chennai real estate market and project execution.
⚠ Risk flags
- High interest cost (18%)
- Loss-making operations (TTM PAT Rs -10 Cr)
- High debt-to-equity ratio (0.97)
- Geographic concentration in Chennai
Key Highlights
Principal repayment of Rs 150 Cr NCDs deferred from June 2026 to June 2027
Debt consists of two tranches: Rs 95 Cr (LICHFL Housing & Infra) and Rs 55 Cr (LICHFL Real Estate Debt)
Company is currently loss-making with a Mar 2026 quarter net loss of Rs 3.19 Cr
Total debt of Rs 207 Cr is significant compared to TTM revenue of Rs 90 Cr
Repayment is heavily dependent on the 1.41x cash coverage ratio from upcoming real estate projects
👀 What to Watch
Monitor the execution and sales velocity of Project Mercury (launching Q3FY26) and Project Rainbow, as these are the primary cash flow sources required to service the 18% interest debt and meet the revised 2027 repayment deadline.
PVP Ventures Pays ₹3.5 Crore Interest on Non-Convertible Debentures
PVP Ventures Limited has confirmed the timely payment of interest on two series of Non-Convertible Debentures (NCDs) with a combined issue size of ₹150 crore. The company disbursed a total interest amount of approximately ₹3.5 crore on June 24, 2026, meeting its scheduled due date. The payments correspond to ISINs INE362A07054 and INE362A07047, which have issue sizes of ₹95 crore and ₹55 crore respectively. This routine disclosure indicates the company is maintaining its debt servicing obligations as per SEBI regulations.
Key Highlights
Total interest payment of ₹3.5 crore (₹2,21,66,667 and ₹1,28,33,333) completed on June 24, 2026.
Serviced debt for two NCD tranches with total issue sizes of ₹95 crore and ₹55 crore.
Payment was made on the actual due date with no delays or defaults reported.
The record date for identifying beneficial owners was June 23, 2026.
Last interest payment for these instruments was previously made on May 20, 2026.
👀 What to Watch
Investors should view the timely debt servicing as a positive indicator of the company's liquidity and credit discipline. No immediate action is required, but monitoring the company's overall debt-to-equity ratio remains advisable.
PVP Ventures Issues Corrigendum for ₹150 Cr NCD Issue; Clarifies 18% Quarterly Coupon & Terms
PVP Ventures Limited has issued a corrigendum to its Key Information Document regarding the private placement of 15,000 Non-Convertible Debentures (NCDs) totaling ₹150 Crores. The update corrects the coupon payment frequency to quarterly (previously stated as annual) at an 18% interest rate. Additionally, it clarifies the total number of debentures as 15,000 (not 1,500) and provides a detailed quarterly repayment schedule ending April 8, 2029.
Key Highlights
Clarified total issue size of 15,000 Senior Secured NCDs with a face value of ₹1,00,000 each, aggregating to ₹150 Crores.
Corrected coupon payment frequency for the 18% interest rate from annual to quarterly compounding.
Revised the final redemption date to April 8, 2029, to align with the 48-month tenor from the allotment date.
Provided a comprehensive repayment schedule detailing principal and interest outflows starting from March 2026.
Confirmed a redemption premium of 1% per annum of the face value payable upon redemption.
👀 What to Watch
Debt investors should note the quarterly payment cycle and the specific repayment milestones starting in 2026. Equity investors should monitor the company's cash flow to ensure it can service this high-cost (18% coupon) debt obligation.
PVP Ventures Completes Interest Payment of Rs 19.11 Crore on NCDs
PVP Ventures Limited has successfully fulfilled its interest payment obligations for two series of Non-Convertible Debentures (NCDs) with a combined issue size of Rs 150 crore. The company disbursed a total interest amount of approximately Rs 19.11 crore on March 27, 2026, which was ahead of the scheduled due date of March 31, 2026. This timely payment covers two specific ISINs with issue sizes of Rs 95 crore and Rs 55 crore respectively. Such adherence to debt schedules reflects positively on the company's current liquidity management and commitment to its creditors.
Key Highlights
Total interest payment of Rs 19.11 crore made across two NCD tranches
Payment completed on March 27, 2026, four days ahead of the March 31 due date
Interest of Rs 12.10 crore paid on NCD issue size of Rs 95 crore (ISIN: INE362A07054)
Interest of Rs 7.01 crore paid on NCD issue size of Rs 55 crore (ISIN: INE362A07047)
Last interest payment for these instruments was previously made on February 6, 2026
👀 What to Watch
Investors should take confidence in the company's ability to service its debt obligations ahead of schedule. No immediate action is required, but it is advisable to monitor the company's long-term debt reduction plans.
PVP Ventures Reports Q3 FY26 Consolidated Net Loss of ₹2.18 Crore Despite Revenue Growth
PVP Ventures Limited reported a significant jump in consolidated total income to ₹10.96 crore for the quarter ended December 31, 2025, up from ₹2.74 crore in the same period last year. However, the company's consolidated net loss widened sharply to ₹2.18 crore compared to a loss of ₹0.08 crore in the previous year's quarter. On a standalone basis, the net loss also increased to ₹4.06 crore from ₹0.74 crore year-on-year. The total comprehensive income for the quarter turned into a loss of ₹2.39 crore against a marginal profit of ₹0.05 crore in Q3 FY25.
Key Highlights
Consolidated total income from operations rose 300% YoY to ₹1,095.58 lacs from ₹273.72 lacs.
Consolidated net loss after tax widened significantly to ₹217.99 lacs from ₹8.48 lacs in the year-ago period.
Standalone net loss for the quarter increased to ₹405.85 lacs compared to ₹73.52 lacs in Q3 FY25.
Consolidated Basic and Diluted EPS for the quarter stood at negative ₹0.09.
Equity share capital remained stable at ₹26,040.37 lacs with a face value of ₹10 per share.
👀 What to Watch
Investors should exercise caution as the company remains loss-making despite a substantial increase in revenue. It is important to analyze the cost structure and exceptional items to understand why the bottom line is not improving with the top line.
PVP Ventures Appoints Dileep Badey as Whole-Time Director for 5 Years
PVP Ventures Limited has announced the appointment of Mr. Dileep Badey as a Whole-Time Director for a five-year term effective March 6, 2026. Mr. Badey, who previously served as the company's Head of Projects, brings over 15 years of experience in real estate development and engineering. Additionally, shareholders approved the appointment of M/s. CNGSN & Associates LLP as the new Statutory Auditor during the Extra-Ordinary General Meeting. These leadership and oversight changes aim to strengthen the company's project execution and governance framework.
Key Highlights
Appointment of Mr. Dileep Badey as Whole-Time Director for a 5-year tenure starting March 6, 2026.
Mr. Badey has over 15 years of experience in project management and real estate development.
M/s. CNGSN & Associates LLP appointed as Statutory Auditor until the next Annual General Meeting.
The appointments were ratified by shareholders at the EGM held on March 6, 2026.
👀 What to Watch
Investors should monitor the company's real estate project delivery timelines, as the new director's technical background in construction management is expected to influence execution efficiency.
PVP Ventures Reports Q3 Net Loss of ₹2.18 Crore; Revenue Rises to ₹8.04 Crore
PVP Ventures reported a net loss of ₹2.18 crore for the quarter ended December 31, 2025, showing an improvement from the ₹3.97 crore loss in the preceding quarter. Revenue from operations grew significantly to ₹8.04 crore compared to ₹5.07 crore in the previous quarter. The company continues to be weighed down by high finance costs, which stood at ₹7.23 crore for the quarter. Investors should note the ongoing legal complexities regarding a ₹218.43 crore loan to a related party, though management maintains that the amount is fully recoverable following recent court orders.
Key Highlights
Net loss narrowed to ₹2.18 crore in Q3 FY26 from a loss of ₹3.97 crore in Q2 FY26.
Revenue from operations increased by 58.5% quarter-on-quarter to ₹8.04 crore.
Finance costs remain high at ₹7.23 crore, representing a significant portion of total expenses.
Outstanding loan of ₹218.43 crore to related party NCCPL is subject to legal proceedings with ED and SEBI.
Non-Executive Director Mrs. P.J. Bhavani resigned effective February 23, 2026, citing no material reasons.
👀 What to Watch
Investors should closely monitor the progress of the ₹218.43 crore loan recovery and the final resolution of land attachments by SEBI and ED. While operational revenue is improving, the high finance costs and legal overhang remain primary risks.
PVP Ventures to Hold EGM on March 6 for Auditor and Director Appointments
PVP Ventures has scheduled an Extra-Ordinary General Meeting (EGM) for March 6, 2026, to seek shareholder approval for key governance changes. The primary agenda includes the appointment of M/s CNGSN & Associates LLP as Statutory Auditors to fill a casual vacancy following the resignation of the previous firm. Additionally, the company is seeking approval for the appointment of Mr. Dileep Badey as a Whole-time Director for a five-year term. Shareholders as of the February 27, 2026, cut-off date will be eligible to vote on these resolutions.
Key Highlights
EGM scheduled for March 6, 2026, to approve auditor and director appointments
Appointment of M/s CNGSN & Associates LLP as Statutory Auditors to fill casual vacancy
Proposed 5-year term for Mr. Dileep Badey as Whole-time Director effective Jan 22, 2026
Voting cut-off date set for Feb 27, 2026, with e-voting from March 3-5
Auditor change follows the resignation of the previous firm, M/s PSDY & Associates
👀 What to Watch
Investors should monitor the reasons for the auditor change and review the new director's profile for alignment with company strategy. No immediate action is required beyond participating in the e-voting process.
